Efferon raises €4.3M from DACH investors to expand sepsis hemoadsorption devices

Efferon, a biotech company developing hemoadsorption devices that remove endotoxins and excessive inflammatory mediators from the bloodstream, has raised €4.3 million from existing private investors in the DACH region, Tech.eu reports tech.euTech.eutech.euOpen source ↗. The devices were originally developed for critical care, including sepsis and septic shock. The technology is approved and used across Europe.

More than 30,000 treatments have been performed with the company's devices, which are distributed in 46 countries. Efferon targets systemic inflammation, which it describes as a core driver of critical conditions, chronic diseases and aging-related decline. On this basis the company is expanding beyond intensive care into broader healthcare and healthy aging applications.

Use of funds

The money will support the commercial expansion of the product portfolio, including Efferon LPS and Efferon NEO, in Europe, India and Latin America. It will also fund further development of the network of 21 distributors, continued regulatory work and the strengthening of the clinical evidence base.

Co-founder and CEO Dima Romashin said the investment will also support R&D, including new devices and research into applications of the technology in adjacent medical fields. It will help train medical teams as well. According to him, these results should lay the foundation for a full Series A round and further progress along the regulatory pathway in the United States tech.euTech.eutech.euOpen source ↗.

Revenue and the Indian market

According to the company, revenue exceeded €1.1 million in 2025. Efferon expects revenue from its intensive care products to reach approximately €5 million in 2027. Subject to successful registration, outpatient products could contribute up to an additional €3 million.

On entering the Indian market, the company plans to combine commercial distribution with systematic collection of real-world implementation data. The study will examine how the technology is integrated into clinical workflows, how medical teams are trained, and which factors support or hinder adoption. The findings are meant to help Efferon develop a model for bringing hemoadsorption to new healthcare markets.

Efferon's stated goal is to make hemoadsorption more accessible to hospitals and patients. The company says this infrastructure should support clinicians' efforts to reduce sepsis mortality alongside timely diagnosis and standard intensive care tech.euTech.eutech.euOpen source ↗.